MLTX: 306% | MoonLake Immunotherapeutics Announced Primary Endpoint HISCR75 Met With 29 Percentage Points Delta Vs Placebo (P=0.0002) At Week 12 In Hidradenitis Suppurativa
FEMY: 194% | Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women
MEDS: 116% | TRxADE HEALTH, Inc. Issues Correction to Press Release Announcing its Anticipated Combination with Superlatus, Inc.